We continue our discussion with Prof. Rohit Loomba (University of California, San Diego, CA, USA) by exploring the results for the phase 2 study investigating pemafibrate in NAFLD.
Part 1 of our video interview can be found here.
His presentation entitled ‘Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator (SPPARM alpha), improves liver stiffness by MRE and serum liver and lipid parameters in NAFLD; a randomized, double-blind, placebo-controlled phase 2 trial’ was given at EASL ILC 2021, 23-26 June.
- What were the aims, inclusion criteria and design of your Phase 2 study? (0:18)
- What were the key study endpoints and what were the MRI responder criteria? (1:26)
- How well were these endpoints met, and what were the safety and tolerability findings? (2:20)
- What will be the next stages in the clinical development of pemafibrate in this indication? (4:33)
Disclosures: Prof. Rohit Loomba serves as a consultant for Anylam/Regeneron, Amgen, Arrowhead Pharmaceuticals, AstraZeneca, Bristol-Myer Squibb, CohBar, Eli Lilly, Galmed, Gilead, Glympse Bio, Inipharm, Intercept, Ionis, Janssen Inc., Madrigal, Metacrine, Inc., NGM Biopharmaceuticals, Novartis, Novo Nordisk, Pfizer, Sagimet, 89bio, and Viking Therapeutics. In addition, his institution has received grant support from Allergan, AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Eli Lilly, Galectin Therapeutics, Galmed Pharmaceuticals, Genfit, Gilead, Intercept, Inventiva, Janssen, Madrigal Pharmaceuticals, Merck, NGM Biopharmaceuticals, Pfizer and Siemens. He is also a co-founder of Liponexus, Inc.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson.
Filmed in coverage of the EASL ILC 2021, 23-26 June.
Share this Video
Related Videos In Liver Disorders
Rifaat Safadi, EASL 2023: CM-101 for the treatment of non-alcoholic steatohepatitis – clinical endpoints and next steps
CM-101, a CCL24 neutralizing antibody, has been recently studied in patients with non-alcoholic steatohepatitis in a phase IIa proof-of-concept study. We caught up with Prof Rifaat Safadi (The Liver Institute, Hadassah Medical Organization, Hadassah Hebrew University Medical Center, Jerusalem, Israel) to discuss the primary and secondary endpoints and how well they were achieved, and the […]
Rifaat Safadi, EASL 2023: CM-101 for the treatment of non-alcoholic steatohepatitis – aims and design
CM-101, a CCL24 neutralizing antibody, has been recently studied in patients with non-alcoholic steatohepatitis in a phase IIa proof-of-concept study. In this touchENDOCRINOLOGY interview, we caught up with Prof Rifaat Safadi (The Liver Institute, Hadassah Medical Organization, Hadassah Hebrew University Medical Center, Jerusalem, Israel) to discuss the mechanism of action of CM-101, and the aims, […]
Paul Brennan: International NASH day 2023
International NASH Day (NASH Day) takes place on the 8th June 2023. It is a public education campaign launched in June 2018 to raise visibility and urgency around fatty liver disease and its more advanced form, nonalcoholic steatohepatitis (NASH), which affects more than 115 million people around the world. We were delighted to talk with […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!